Story thread · 2 reports / 2 sources
New obesity drug leads to greater weight loss than ingredient in Zepbound
dailymail.co.uk · 2h
How the coverage leans
Across 2 sources · syndicated copies counted once
A new obesity drug from pharma giant Novo Nordisk has been shown to lead to greater weight loss than a popular competitor medication, new research shows.
First report: Novo Nordisk’s next-gen weight loss drug outperforms Zepbound in new trial — thehill.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.